Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.
Kovarik
J M
JM
Sandoz Pharma Ltd., Basle, Switzerland.
Rawlings
E
E
Sweny
P
P
Fernando
O
O
Moore
R
R
Griffin
P J
PJ
Fauchald
P
P
Albrechtsen
D
D
Sodal
G
G
Nordal
K
K
Amlot
P L
PL
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007680:Kidney Neoplasms / Q000276:immunology*; D008297:Male; D051379:Mice; D008875:Middle Aged; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins